Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
GAX-CI Chemotherapy Followed by Maintenance Olaparib and Pembrolizumab in Untreated Metastatic Pancreatic Cancer
NCT04753879Phase 2Completed
- Sponsor
- Sidney Kimmel Comprehensive Cancer Center
- Start
- Sep 2021
- Primary completion
- May 2026
- Modality
- Immune Checkpoint Inhibitors, Recombinant Proteins and Enzymes, Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of olaparib, pembrolizumab in pancreatic ductal adenocarcinoma (PDAC), sponsored by Sidney Kimmel Comprehensive Cancer Center. Started Sep 2021; status: completed.
02
Drugs
olaparibpembrolizumab
03
Conditions
pancreatic ductal adenocarcinoma (PDAC)
Beyond the preview
Go deeper on NCT04753879.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04753879.